Evidence map›Paper›PMID 37162541›Full record

ArticleNaunyn-Schmiedeberg's archives of pharmacology2023

Modulatory effect of liraglutide on doxorubicin-induced testicular toxicity and behavioral abnormalities in rats: role of testicular-brain axis.

Shorouk A Alafifi, Sara A Wahdan, Alzahraa A Elhemiely, Doaa A Elsherbiny, Samar S Azab

RetractedOpen access · hybridAbstract readRetracted Publication
In one paragraph

Article in Naunyn-Schmiedeberg's archives of pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Shorouk A AlafifiPharmacology & Toxicology Department, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt.
Sara A WahdanPharmacology & Toxicology Department, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt.
Alzahraa A ElhemielyResearcher of Pharmacology, Egyptian Drug Authority, Cairo, Egypt.
Doaa A ElsherbinyPharmacology & Toxicology Department, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt.
Samar S AzabPharmacology & Toxicology Department, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, Egypt. samar_saad_azab@pharma.asu.edu.eg.
Ain Shams University · EGEgyptian Government · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Doxorubicin (DOX) is a powerful chemotherapeutic agent used in many types of malignancies. However, its use results in testicular damage. DOX-induced testicular damage results in low level of serum testosterone which may affect cognitive function. The current study investigated the protective effect of liraglutide (50, 100 μg/kg/day) in testicular toxicity and the consequent cognitive impairment induced by DOX. DOX treatment reduced sperm count (62%) and sperm motility (53%) and increased sperm abnormalities (786%), as compared to control group. DOX also reduced serum testosterone level (85%) and the gene expression of testicular 3β-HSD (68%) and 17β-HSD (82%). Moreover, it increased testicular oxidative stress (MDA and GSH) by 103% and 59%, respectively, apoptotic (caspase-3 and P53) by 996% and 480%, respectively. In addition, DOX resulted in increasing autophagic markers including PAKT, mTOR, and LC3 by 48%, 56%, and 640%, respectively. Additionally, rats' behavior in Y-maze (60%) and passive avoidance task (85%) was disrupted. The histopathological results of testis and brain supported the biochemical findings. Treatment with liraglutide (100 μg/kg/day) significantly abrogated DOX-induced testicular damage by restoring testicular architecture, increasing sperm count (136%) and sperm motility (106%), and decreasing sperm abnormalities (84%) as compared to DOX group. Furthermore, liraglutide increased serum testosterone (500%) and steroidogenesis enzymes 3β-HSD (105%) and 17β-HSD (181%) along with suppressing oxidative stress (MDA and GSH) by 23% and 85%, respectively; apoptotic (caspase-3 and P53) by 59% and55%, respectively; and autophagic markers including PAKT, mTOR, and LC3 by 48%, 97%, and 60%, respectively. Moreover, it enhanced the memory functions in passive avoidance and Y-maze tests (132%). In conclusion, liraglutide is a putative agent for protection against DOX-induced testicular toxicity and cognitive impairment through its antioxidant, antiapoptotic, and antiautophagic effects.

Indexed as

LiraglutideTestisAnimalsAntioxidantsBrainCaspase 3DoxorubicinMaleOxidative StressRatsSemenSperm MotilityTestosteroneTOR Serine-Threonine KinasesTumor Suppressor Protein p53AntioxidantsCaspase 3DoxorubicinLiraglutideTestosteroneTOR Serine-Threonine KinasesTumor Suppressor Protein p53AutophagyCognitive impairmentDOXLiraglutidePI3 kinase/Akt/mTOR pathwayTesticular damage

Identifiers

PMID37162541
PMCPMC10567954
OpenAlexW4376121414

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.